Global Animal Model Substitutes Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Animal Model Substitutes Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Animal model substitutes use artificially cultured cells or tissue lines, or microfluidic on-chip organ systems, rather than live animals. Generally, animals such as mice are not accurate models for human drugs. It is generally agreed that reducing the number of animals used and improving testing to reduce suffering should be important goals for the industries involved. As with traditional toxicology research, research using alternative models is for the ultimate benefit of human health, environmental health and/or the health and well-being of the test species itself.

Market Overview:

The latest research study on the global Animal Model Substitutes market finds that the global Animal Model Substitutes market reached a value of USD 1519.62 million in 2022. It’s expected that the market will achieve USD 2132.53 million by 2028, exhibiting a CAGR of 5.81% during the forecast period.

Influence of COVID-19 Outbreak on Animal Model Substitutes Industry Development

The animal model substitute industry is an industry under the pressure of COVID-19. As people self-isolate at home, many experimental research activities have to be cancelled.

The key point here is that the impact of COVID-19 on the industry may vary greatly from product to product and service to service in different industries. Indeed, the company reported negative trends in one aspect of its business, while reporting positive trends in other areas. Some indicators have decreased, while others have increased unexpectedly.

One of the most frustrating effects of the spread of COVID-19 is the disruption to the supply chain. Although the research and production of animal model substitutes are being carried out at the same time, they will inevitably be affected by the epidemic. This is mainly reflected in the fact that R&D personnel will be isolated at home for personal safety, and the raw materials used for production will be affected by transportation interruptions.

Drivers

Non-animal testing market technologies are being developed to reduce the use of animals, fast track the drug development process and develop costeffective methods. These alternatives to animal testing market technology are receiving increasing attention.
Protests by animal welfare organizations (such as Animal Ethical Treatment of People (PETA) and International Cruelty International) have put tremendous pressure on federal agencies and companies that perform animal testing. They must reduce or eliminate the animal testing market and use alternative animals. Test method (if applicable).
Because testing of alternatives to animal models is cost-effective, more efficient, and often time-saving. Protests by animal welfare organizations (such as Animal Ethical Treatment of People (PETA) and International Cruelty International) have put tremendous pressure on federal agencies and companies that perform animal testing. They must reduce or eliminate the animal testing market and use alternative animals. Test method (if applicable).
The pharmaceutical industry is increasingly inclined to adopt alternative methods because the industry is committed to increasing productivity and reducing adverse reactions. The implementation of a series of extremely strict sales bans on animal testing reflects the consistency of technology (stem cells, imaging) and social development (environmental issues, consumer influence), and ultimately affects the use of animal testing in the cosmetics industry and the pharmaceutical industry.

Region Overview:

From 2023-2028, Europe is estimated to witness robust growth prospects.

Company Overview:

BioIVT is one of the major players operating in the Animal Model Substitutes market, holding a share of 3.7% in 2021.

BioIVT, formerly BioreclamationIVT, is the world's leading provider of high-quality biological specimens and value-added services. The company focuses on samples for control and disease states, including human and animal tissues, cell products, blood and other biological fluids.

Cyprotex is the world's largest contract research organization, specializing in preclinical ADME Tox. Cyprotex provides the most comprehensive ADME Tox CRO service.

Segmentation Overview:

Among different product types, In Vitro testing segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Research & development segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Animal Model Substitutes market covered in Chapter 3:

Organovo Holdings, Inc
BioIVT
Cyprotex
Nortis Inc.
Others
MatTek
InSphero
Tara Biosystems
ReproCell Inc
Episkin
Mimetas
Emulate, Inc
HuRel Corporation
Abzena
SGS SA

In Chapter 4 and Chapter 14.2, on the basis of types, the Animal Model Substitutes market from 2018 to 2029 is primarily split into:

In Vitro testing
In Silico Modeling
Human Volunteers
Stem cell research
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Animal Model Substitutes market from 2018 to 2029 covers:

Research & development
Production and quality control
Academics

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)